When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics (ADMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently has an average brokerage recomme ...

Have you been paying attention to shares of Adma Biologics (ADMA) ? Shares have been on the move with the stock up 22.9% over the past month. The stock hit a new 52-week high of $17.04 in the previous session. Adma Biologics has gained 263.9% since the start of the year compared to the 6.7% move for the Zacks Medical sector and the -2.3% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it h ...

Adma Biologics (ADMA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 62.50%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.05 per share when it actually produced earnings of $0.08, delivering a surprise of 60%.Over the last four quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State or ...

Exhibit 99.1 ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update 2Q 2024 Total Revenue of $107.2 Million, a 78% Increase Y-o-Y 2Q 2024 GAAP Net Income of $32.1 Million, a $38.4 Million Increase Y-o-Y 2Q 2024 Adjusted EBITDA(1) of $44.5 Million, a Nearly 600% Increase Y-o-Y Commercial Scale Production of ADMA's Innovative Biologics Manufacturing Process Supports a Potential Yield Enhancement of Approximately 20% from Same Starting Plasma FY 2024 and 2025 Total Revenue ...

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2024 financial results on August 8, 2024, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its fin ...

Group 1 - Adma Biologics (ADMA) stock closed at $12.28, with a daily increase of +0.82%, underperforming the S&P 500's gain of 1.08% [1] - The stock has increased by 6.84% over the past month, outperforming the Medical sector's gain of 0.71% and the S&P 500's decline of 0.44% [1] - Upcoming earnings report is projected to show earnings of $0.08 per share, reflecting a year-over-year growth of 500%, with revenue expected at $87.03 million, up 44.75% from the previous year [1] Group 2 - Recent analyst estimate changes for Adma Biologics indicate a positive outlook, with no change in the Zacks Consensus EPS estimate over the past month [2] - Adma Biologics currently holds a Zacks Rank of 1 (Strong Buy), which has historically yielded an average annual return of +25% since 1988 [2] Group 3 - Adma Biologics is trading at a Forward P/E ratio of 34.8, which is higher than the industry average of 24.56, suggesting a premium valuation [3] - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 86, placing it in the top 35% of over 250 industries [3]

bymuratdeniz ADMA Biologics, Inc. (NASDAQ:ADMA) specializes in developing and commercializing plasma-derived products for infectious diseases. However, ADMA’s market mostly focuses on immune-compromised patients. The company’s IP portfolio centers around three FDA-approved medications: Asceniv, Bivigam, and Nabi-HB. ADMA’s revenue streams primarily come from their FDA-approved products, with additional income from patented immunotechnology and contract development and manufacturing organization [CDMO] se ...

We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s (ADMA) portfolio of marketed products and other pipeline updates when it reports second-quarter 2024 results.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products, namely – Bivigam (to ...

Adma Biologics (ADMA) closed the most recent trading day at $13.05, moving -1.81% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.78% for the day. On the other hand, the Dow registered a loss of 1.29%, and the technology-centric Nasdaq decreased by 0.7%.The infectious disease drug developer's shares have seen an increase of 25.14% over the last month, surpassing the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14%.Market participants will be ...